Isoechoic Renal Tumors: A Case Report and Literature Review
- Autori: Sinatra, N.; Geraci, G.; Palumbo, R.; Oddo, G.; Zichittella, G.; Cirafici, E.; Sorce, A.; Mulè, G.; Carollo, C.
- Anno di pubblicazione: 2025
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/697331
Abstract
: Background and Clinical Significance: Isoechoic renal tumors, defined as masses demonstrating echogenicity similar to normal renal parenchyma, represent a significant diagnostic challenge in contemporary ultrasonographic practice. These lesions, occurring in 5-12% of all renal masses, frequently escape detection on conventional ultrasound, leading to delayed diagnosis and potentially adverse oncological outcomes. Isoechoic renal tumors encompass both benign and malignant entities, with clear cell renal cell carcinoma representing 65-70% of malignant cases. Conventional ultrasound shows limited sensitivity (48-67%) for detecting isoechoic masses, while contrast-enhanced ultrasound achieves detection rates of 94-98%. Multiparametric MRI and dual-energy CT provide superior characterization, with accuracy rates of 85-92% for differentiating benign from malignant lesions. Case Presentation: We describe the case of an 80-year-old male in whom a 2.4 cm isoechoic renal mass was incidentally detected during abdominal ultrasound performed for chronic kidney disease monitoring. Contrast-enhanced CT confirmed a solid, hypervascular lesion with wash-out characteristics. Given the patient's age, comorbidities, and tumor characteristics, multidisciplinary evaluation led to an active surveillance strategy. At 6-month follow-up, the lesion remained stable. Conclusions: Isoechoic renal tumors require multimodal diagnostic approaches and individualized management strategies. Emerging technologies, including artificial intelligence-enhanced ultrasound systems and radiomic-based decision support tools, are undergoing clinical validation and may improve detection and characterization. Investigational approaches such as liquid biopsy and novel PET tracers targeting carbonic anhydrase IX are in early development. Translation of these technologies into clinical practice will require prospective validation, standardization of protocols, and demonstration of cost-effectiveness.
